Merck

Thyroid disorders in colorabia

ABOUT THYROID DISORDERS

Thyroid hormones are produced by the thyroid gland in the neck, and are essential for normal bodily function.¹ Thyroid disorders occur when there is an imbalance in the production of these hormones. There are two categories:

Hypothyroidism: a deficiency of thyroid hormones due to the thyroid gland producing too little thyroid hormone. Symptoms may include weight gain, fatigue, depression, memory problems, muscle weakness and impaired development in children.¹ Approximately 4–10% of the global population have hypothyroidism.² **Hyperthyroidism: an excess of thyroid hormone** due to an overactive thyroid gland. Symptoms may include sudden weight loss, fatigue, mood swings, rapid heartbeat, increased appetite, muscle weakness, intolerance of heat and enlarged thyroid gland.¹

Awareness of these disorders is low, and symptoms are difficult to detect as they can be easily confused with symptoms of other conditions or natural signs of aging.³ This can cause significant delays to an accurate diagnosis, sometimes up to two years.⁴

Thyroid disorders are a public health issue impacting maternal and child health, non-communicable disease reduction and healthy aging. As a result, thyroid disorders are strongly connected to many of the health Sustainable Development Goals.⁵

As people age and live with an increasing number of comorbidities, early detection and optimal treatment of thyroid disorders will become essential. Treatment aims to return the thyroid hormone levels to a normal range, and for hypothyroidism it has also been shown to improve quality of life.⁶

WHY WE NEED TO ACT NOW

Thyroid disorders are particularly harmful in certain groups

- Older people with thyroid disorders are at increased risk of morbidity and mortality.⁷
- People with cardiovascular disease (CVD) and thyroid disorders are at increased risk of morbidity or mortality.⁸
- Pregnant women with hypothyroidism are more likely to suffer from obstetric and fetal complications such as impaired fetal cognitive development, preterm birth and pregnancy loss.⁹

Current screening and identification of thyroid disorders are suboptimal

Late identification of thyroid disorders risks progression to more severe symptoms,⁴ which may lead to decreased quality of life.¹⁰ Despite this:

- The risk-based approach currently used may miss 30–55% of pregnant women with hypothyroidism.¹¹
- Almost 20% of Latin American physicians do not perform any screening for hypothyroidism in pregnancy, and 10% do not have an overarching strategy for screening.¹²

Adequate management of thyroid disorders is part of sustainable and integrated care systems

The detection and management of thyroid disorders will take on additional importance in the context of a growing burden of CVD and non-communicable diseases and an aging population.¹³ These issues will contribute to higher spending on healthcare,¹⁴ for which many countries are ill prepared.

Data on thyroid disorders in Latin America are lacking

Information on the health and economic burden of thyroid disease in Latin America is very limited and there is an overreliance on international data. This means that we are likely to underestimate the burden of thyroid disorders.



WHAT IS HAPPENING IN COLOMBIA?

Key facts about thyroid disorders in Colombia

| Epidemiology | Hypothyroidism | Approximately 5 million people in Colombia live with hypothyroidism (overt and subclinical) ¹⁵ 5.9% of the population are estimated to have subclinical hypothyroidism. ¹⁶ This rises to 15.6% in women aged 16–35 ¹⁷ |
|--------------|---------------------------------------|--|
| | Hyperthyroidism | 0.7% of the population are estimated to have overt hyperthyroidism¹⁶ 1.3% of the population are estimated to have subclinical hyperthyroidism¹⁶ |
| Policy | Clinical guidelines | International guidelines are used, as national guidelines are not yet available |
| | National patient or advocacy group | No national groups exist for thyroid disorders; however, thyroid cancer groups exist |



Access to high-quality healthcare and specialists can be variable

Healthcare is accessible to 94.6% of Colombians under government programmes and private insurance.¹⁸ However, access to high-quality healthcare services is impacted by geography and financial barriers.^{19 20}

Due to the limited number of endocrinologists in Colombia, access to these specialists can be challenging.²⁰ Therefore, general practitioners (GPs) often play a significant role in managing cases of hypo- and hyperthyroidism. However, to do this, GPs should be better supported to manage the condition through education and clinical guidelines.²⁰

Lack of therapeutic guidelines negatively impacts care

The absence of nationally specific guidelines for the treatment thyroid disorders is likely to have impacted patient health.²¹ It is unclear to what extent clinicians are aware of international guidelines,²⁰ and the quality of care and frequency of monitoring of thyroid disorders is highly variable between different healthcare professionals.

POLICY RECOMMENDATIONS

Thyroid disorders require a comprehensive integrated policy response. We recommend that decision-makers across Latin America take the following actions:

1 Improve the implementation of screening for thyroid disorders:

- Implement aggressive risk-based case finding, • with a focus on adults over 60 years old, those with existing CVD and pregnant women.
- Enable primary care physicians to carry out . risk-based case finding with clinical protocols and continuing medical education.
- 2 Ensure regular thyroid hormone checks for pregnant women and those planning to become pregnant:
- Strengthen monitoring of thyroid disorders • among women.
- Include thyroid hormone tests as part . of routine tests for pregnant women.
- Establish country-specific diagnostic reference values for pregnant women.

3 Raise awareness of the links between thyroid disorders and CVD:

- Raise awareness of thyroid disorders among people with CVD, cardiologists and GPs.
- Support cardiologists to test for suboptimal • thyroid function.
- 4 Regularly monitor population-wide iodine and sodium intake levels:
- Monitor the population-level iodine and sodium intake and optimize salt iodization levels accordingly.



References

- Wallace RB, Stone MB. 2003. Medicare coverage of routine screening for thyroid dysfunction. Washington DC: National Academies Press 1.
- Udovcic M, Pena RH, Patham B, et al. 2017. Hypothyroidism and the Heart. Methodist Debakey Cardiovasc J 13(2): 55-59 2.
- Benseñor IM, Goulart AC, Lotufo PA, et al. 2011. Prevalence of thyroid disorders among older people: results from the São Paulo Ageing & Health Study. *Cad Saude Publica* 27: 155-61 3.
- InSites Consulting. 2017. Hypothyroidism late-stage diagnosis: mapping out the journey and opportunities to shorten the process. Internal Merck resource: InSites Consulting 4.
- . World Health Organization. 2018. SDG 3: Ensure healthy lives and promote wellbeing for all at all ages. Available from: https:// www.who.int/sdg/targets/en/ [Accessed 28/05/19] 5.
- dos Santos Vigário P, Vaisman F, Coeli CM, *et al.* 2013. Inadequate levothyroxine replacement for primary hypothyroidism is associated with poor health-related quality of life-a Brazilian multicentre study. *Endocrine* 44(2): 434-40 6.
- Mitrou P, Raptis SA, Dimitriadis G. 2011. Thyroid disease in older people. *Maturitas* 70(1): 5-9 7.
- Gencer B, Collet T-H, Virgini V, *et al.* 2013. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. *Endocr Metab Immune Disord Drug Targets* 13(1): 4-12 8.
- Reid SM, Middleton P, Cossich MC, *et al.* 2013. Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy. *Cochrane Database Syst Rev* (5): 10.1002/14651858.CD007752.pub3 Bianchi GP, Zaccheroni V, Solaroli E, *et al.* 2004. Health-related quality of life in patients with thyroid disorders. *Qual Life Res* 13(1): 45-54 9. 10.
- Aghajanian P, Spencer CA, Wilson ML, et al. 2016. Evaluation of risk-factor-based screening for thyroid peroxidase antibody positivity in pregnancy. *Clin Endocrinol (Oxf)* 84(3): 417-22 11.
- Medeiros MFdS, Cerqueira TLdO, Silva Junior JC, *et al.* 2014. An international survey of screening and management of hypothyroidism during pregnancy in Latin America. *Arq Bras Endocrinol Metabol* 58(9): 906-11 12.

- Anauati MV, Galiani S, Weinschelbaum F. 2015. The rise of noncommunicable diseases in Latin America and the Caribbean: challenges for public health policies. Lat Am Econ Rev 24(1): 11
- Organisation for Economic Co-operation and Development (OECD). 2019. Society at a Glance 2019: OECD Social Indicators. Paris, France: OECD Publishing 14.
- Machado-Alba JE, Medina-Morales DA, Valladales-Restrepo LF, et al. 2018. Patrones de prescripción de medicamentos antitiroideos en una población de Colombia. Acta Med Colomb 43: 150-55
- Carmona Carmona CA, Bedoya PA, Acevedo JB, et al. 2018. Prevalence of Thyroid Disorders in an Institution Providing Health Services in Medellin-Colombia. *Transl Biomed* 9(2): 149 16.
- Maya LFF, Clavijo AMG, Garcés MF, et al. 2017. ¿ Es mandatoria la tamización de disfunción tiroidea en toda mujer en la consulta preconcepcional?: Aportes de un estudio local. *Revista Colombiana* de Endocrinología, Diabetes & Metabolismo 2(3): 35-43
 Micinaria de Colombiana
- de Endocrinologia, Diabetes & Metabolismo 2(3): 35-43
 18. Ministerio de Salud. 2019. Comportamiento del aseguramiento. Available from: https://www.minsalud.gov.co/ proteccionsocial/Regimensubsidiado/Paginas/coberturas-del-regimen-subsidiado.aspx [Accessed 01/04/19]
 19. Tafur Calderon LA, Prada SI. 2019. El Sistema General De Seguridad Social En Salud De Colombia. Cali, Colombia: Centro de Estudios en Protección Social y Economía de la Salud (PROESA)
- Lopez-Jaramillo P. 2019. Interview with Christine Merkel at The Health Policy Partnership [Telephone]. 20 March 2019
- Machado-Alba J, Valencia-Marulanda J, Jiménez-Canizales C, *et al.* 2014. Patrones de prescripción de hormonas tiroideas en una población colombiana. *Rev Panam Salud Publica* 36: 80-86 21.

Health Policy Partnership

This report was written by The Health Policy Partnership with funding from Merck. The report is non-promotional; none of its content is specific or biased to any particular treatment or therapy.

MERCKgroup.com